NCT06092606View on ClinicalTrials.gov

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
CancerHeart FailureArrhythmiaDoxorubicin Induced CardiomyopathyDoxorubicin Adverse Reaction
Interventions
DRUG

Control group:DH001 placebo

Dosage: DH001 placebo (8 tablets)

DRUG

Trial group: DH001 low-dose group

Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)

DRUG

Trial group: DH001 high-dose group

Dosage: DH001 400mg (8 tablets).

Trial Locations (1)

Unknown

RECRUITING

Harbin Institute of Hematology and Cancer, Harbin

All Listed Sponsors
lead

Monyan Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY